Table 1.

Patient demographics (N = 1,526 patients; includes 111 patients treated with immunotherapy).

TMB level, N (%)a
VariableGroupPatients all TMB, N (%)Immunotherapy treated, N (%)LowIntermediateHighVery highPb
OverallPatients1,526111 (7%)1,034 (68%)337 (25%)62 (4%)53 (3%)
Age, y<60892 (58%)66 (7%)649 (73%)198 (22%)23 (3%)22 (2%)1.21 × 10−7
≥60634 (42%)45 (7%)385 (61%)179 (28%)39 (6%)31 (5%)
SexWomen775 (51%)59 (8%)523 (67%)208 (27%)29 (4%)15 (2%)0.74
Men751 (49%)52 (7%)511 (68%)169 (23%)33 (4%)38 (5%)
EthnicityAfrican-American55 (4%)2 (4%)33 (60%)20 (36%)2 (4%)0 (0%)0.36
Asian147 (10%)10 (7%)115 (78%)28 (19%)3 (2%)1 (1%)2.4 × 10−3
Hispanic207 (14%)13 (6%)157 (76%)44 (21%)5 (2%)1 (0%)3.1 × 10−3
Other65 (4%)5 (8%)46 (71%)17 (26%)0 (0%)2 (3%)0.48
NHW1,052 (69%)81 (8%)683 (65%)268 (25%)52 (5%)49 (5%)5.0 × 10−5
Smoking historyNo915 (60%)67 (7%)670 (73%)198 (22%)24 (3%)23 (3%)4.5 × 10−9
Yes611 (40%)44 (7%)364 (60%)179 (29%)38 (6%)30 (5%)
Type of cancerBrain160 (10%)10 (6%)129 (81%)27 (17%)3 (2%)1 (1%)1.3 × 10−4
Breast158 (10%)22 (14%)106 (67%)48 (30%)4 (3%)0 (0%)0.76
Colon/rectum148 (10%)7 (5%)93 (63%)47 (32%)3 (2%)5 (3%)0.29
Hematologic205 (13%)4 (2%)173 (84%)26 (13%)5 (2%)1 (0%)3.9 × 10−8
Lung171 (11%)11 (6%)89 (52%)69 (40%)9 (5%)4 (2%)2.3 × 10−5
Cutaneous98 (6%)8 (8%)23 (23%)25 (26%)21 (21%)29 (30%)2.2 × 10−16
Other586 (38%)49 (8%)421 (72%)135 (23%)17 (3%)13 (2%)3.0 × 10−3
GroupLow TMBIntermediate TMBHigh TMBVery high TMB
Median OS (weeks) by Cox (95% CI)From biopsyc155 (137–184)101 (83–131)151 (105–NA)384 (155–NA)
From advanced disease239 (209–284)174 (136–190)192 (151–NA)350 (209–NA)
  • Abbreviation: NA, not applicable.

  • aLow TMB defined as ≤5/Mb, intermediate TMB defined as >5 and ≤20/Mb, high TMB defined as >20 and ≤50/Mb, and very high TMB defined as >50 mutations/Mb.

  • bProbability calculated from Kruskal–Wallis as appropriate with aggregates used as reference for variables with >2 categories; significant values with Bonferroni corrected α are bolded. P values for weeks followed represent distribution of time followed between the TMB levels.

  • cPatients missing date of biopsy were omitted.